There's a growing recognition that European governments can no longer just be regulators; they must actively compete for biotech investment and clinical trials. This requires treating their country's R&D environment as a product with an "attractive offering" to win against global competitors.
A key operational hurdle for European clinical trials is the absence of a mandatory response timeline for regulators. Unlike the US FDA, which must respond to trial applications within 30 days, European regulators have no fixed "shot clock," creating uncertainty and delays that deter trial sponsors.
The competitive pressure for European biotech to speed up clinical trials is a direct response to Chinese companies. China's ability to generate early human data quickly has raised the global bar for investment and partnering, compelling Europe to become more efficient to compete for capital.
Beyond funding and regulatory hurdles, Europe's restrictive drug pricing environment is a fundamental threat. It discourages pharmaceutical companies, including Europe's own, from investing in the region as they prioritize the more profitable US market. This ultimately undermines the entire local R&D ecosystem.
The Institute of Organic Chemistry and Biochemistry (IOCB) in Prague demonstrates how academic centers can build entire ecosystems. By using royalty income from major drug discoveries, it funded a dedicated technology transfer company (IOCB Tech) and even a US branch, creating a self-sustaining innovation engine.
European pension funds invest just 0.02% in venture capital (vs. 2% in the US) because their core mission is capital preservation. Overcoming this requires more than just education; it needs structural solutions like EIB-backed fund-of-funds vehicles to simplify and de-risk VC exposure for these conservative institutions.